Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab + Chemotherapy in Resectable Locally Advanced Oral Cavity and Larynx SCC
NCT07400094Phase 2Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in squamous cell carcinoma of the oral cavity (OSCC) and squamous cell carcinoma of the larynx (SCCL). Primary endpoints: Pathological Complete Response Rate and Major Pathological Response Rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)squamous cell carcinoma of the larynx (SCCL)
Beyond the preview
Go deeper on NCT07400094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400094.